Hormone Therapy for Menopause
Also known as: ERT, Estrogen replacement therapy, HRT, Hormone replacement therapy, MHT
Methodology & AI Transparency ⓘ
Hormone Therapy for Menopause Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is hormone therapy for menopause? Menopause is the time in a woman's life when her menstrual periods stop.
- 2 Real-world patient consensus: Clinical coding for Hormone Therapy for Menopause uses ICD-10 E28.3.5 across Menopause & HRT specialty care.
- 3 Typical cash cost range: Differential triage of Hormone Therapy for Menopause (E28.3.5) utilizes individualized transdermal estradiol in Hormone Therapy for Menopause (E28.3.5: + micronized progesterone).
- 4 Top reported side effects / signs: Objective lab/clinical target for Hormone Therapy for Menopause: 17-Beta Estradiol & in Hormone Therapy for Menopause (E28.3.5: FSH (Contextual)) (Symptom-guided physiological target (E28.3.5)) and DEXA Bone Density in Hormone Therapy for Menopause (E28.3.5: & Fasting ApoB).
Ask our AI Specialists anything about Hormone Therapy for Menopause
What Is Hormone Therapy for Menopause?
What is hormone therapy for menopause? Menopause is the time in a woman's life when her menstrual periods stop. It is a normal part of aging. During menopause, the body makes much lower amounts of the hormones estrogen and progesterone. Hormone therapy for menopause involves taking estrogen, with or without progesterone (or a similar hormone called progestin). The goal is to replace some of the hormones the body no longer makes and help relieve menopausal symptoms. What does hormone therapy for menopause treat? In the years leading up to menopause, and during menopause, hormone levels can rise and fall.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hormone Therapy for Menopause (ICD-10 E28.3.5) is driven by urogenital mucosal thinning [Hormone Therapy for Menopause E28.3.5]; Cross-referenced with NIH MeSH (Menopause, Hormone Replacement Therapy), specialists in Menopause, Perimenopause & Hormone Therapy monitor DEXA Bone Density in Hormone Therapy for Menopause (E28.3.5: & Fasting ApoB) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Are pregnant or think that you may be pregnant
- • Have unexplained vaginal bleeding
- • Presentation of Hormone Therapy for Menopause (E28.3.5): midsection body-composition shift, in Hormone Therapy for Menopause (E28.3.5: joint stiffness, and)
- • Secondary Hormone Therapy for Menopause clinical sign: vasomotor hot flashes, in Hormone Therapy for Menopause (E28.3.5: sudden facial/chest warmth,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hormone Therapy for Menopause Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E28.3.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Menopause, Perimenopause & Hormone Therapy | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 17-Beta Estradiol & in Hormone Therapy for Menopause (E28.3.5: FSH (Contextual)) | Symptom-guided physiological target (E28.3.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Bone Density in Hormone Therapy for Menopause (E28.3.5: & Fasting ApoB) | T-Score > -1.0; ApoB < 75 mg/dL (E28.3.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & HbA1c in Hormone Therapy for Menopause (E28.3.5: Midlife Panel) | TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (E28.3.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hormone Therapy for Menopause
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Kineret (Anakinra) Kineret • RxCUI RXN-B66658234 | Interleukin-1 Receptor Antagonist | 83% | $1.1300 | $ 89.86 /mo |
| Hyoscyamine Sulfate Hyosyne, Nulev • RxCUI 1046982 | Gastrointestinal Agent | 78% | $0.1607 | $ 7.80 /mo |
| Sertraline HCl (Sertraline Hydrochloride) Sertraline HCl • RxCUI 251201 | Serotonin Reuptake Inhibitor | 76% | $1.1457 | $ 90.99 /mo |
| Bicalutamide Casodex • RxCUI 199123 | Androgen Receptor Inhibitor | 86% | $0.3944 | $ 12.63 /mo |
| Alprostadil Prostin Vr Pediatric, Edex • RxCUI 105467 | Prostaglandin Analog | 81% | $223.3550 | $ 185.00 /mo |
| Repository Corticotropin Acthar, Purified Cortrophin Gel • RxCUI RXN-630048712-2398 | Adrenocorticotropic Hormone | 94% | $3.0900 | $ 133.64 /mo |
| Chorionic Gonadotropin Chorionic Gonadotropin Generic • RxCUI 896854 | FDA Prescription Therapeutic Agent | 93% | $250.6695 | $ 185.00 /mo |
| Orphenadrine Citrate Orphenadrine Citrate Generic • RxCUI 994521 | Muscle Relaxant | 76% | $0.4309 | $ 25.95 /mo |
| Omlonti (Omidenepag Isopropyl) Omlonti • RxCUI RXN-B84826002 | Prostaglandin E2 Receptor Agonist | 90% | $2.4500 | $ 184.90 /mo |
| Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) Tecentriq Hybreza • RxCUI RXN-B50242933 | Endoglycosidase | 91% | $1.2100 | $ 95.62 /mo |
| Lemtrada (Alemtuzumab) Lemtrada • RxCUI RXN-B584680200 | CD52-directed Cytolytic Antibody | 79% | $3.0100 | $ 225.22 /mo |
| Omnitrope (Somatropin) Omnitrope • RxCUI RXN-B07813004 | Recombinant Human Growth Hormone | 75% | $855.3223 | $ 640.00 /mo |
| Macrilen (Macimorelin Acetate) Macrilen • RxCUI RXN-B01691401 | Growth Hormone Secretagogue Receptor Agonist | 83% | $1.9500 | $ 148.90 /mo |
| Sodium Phenylbutyrate Buphenyl, Pheburane • RxCUI 199369 | Nitrogen Binding Agent | 91% | $0.2000 | $ 307.97 /mo |
| Bisacodyl Laxative, Onelax • RxCUI 308753 | Stimulant Laxative | 86% | $0.3586 | $ 23.02 /mo |
| Mestinon (Pyridostigmine Bromide) Mestinon • RxCUI 903843 | Cholinesterase Inhibitor | 86% | $0.5897 | $ 8.48 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hormone Therapy for Menopause)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and: What a 4,804-Participant Study Found Pertuzumab improved IDFS in all subgroups, with the greatest improvement in HER2 FISH-low/estrogen receptor-positive tumors. Journal of the National Cancer Institute • 2026-08-01 • Phase III Randomized Trial | N = 4,804 | 96/100 | PMID 41934626 ↗ |
| New Insights on Age-related real-world benefits and safety of Darolutamide Plus: What a 1,086-Participant Study Found In the 219 patients aged ≥75 yr in ARASENS, darolutamide demonstrated improved efficacy versus placebo and favorable safety, consistent with the findings in patients aged <75 yr. European urology oncology • 2026-06-15 • Phase III Randomized Trial | N = 1,086 | 96/100 | PMID 41193271 ↗ |
| New Insights on Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable: What a 1,022-Participant Study Found This pooled analysis demonstrated efficacy of fezolinetant vs. Current medical research and opinion • 2025-02-15 • Randomized Controlled Trial | N = 1,022 | 96/100 | PMID 40044127 ↗ |
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on Reproductive hormone characteristics of obese Chinese patients with polycystic: What a 4,554-Participant Study Found Conversely, they exhibited significantly higher testosterone (T) ( p = 0.001) levels. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2025-12-15 • Meta-Analysis | N = 4,554 | 94/100 | PMID 40287875 ↗ |
Hormone Therapy for Menopause Patient Community & “People Like Me” Threads
Filter Hormone Therapy for Menopause community threads and patient logs by age, biological sex, dosage, and treatment duration.